

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1623

PATENT

Rev 06/04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

AUG 02 2005

In re application : Mitchell P. Fink et al.
Application No. : 10/659,063
Filed : September 10, 2003
Confirmation No. : 3827
For : EXTRACELLULAR NAD+ AND cADPR AS POTENT
ANTI-INFLAMMATORY AGENTS
Examiner : Henry, Michael C.
Attorney's Docket : UPITT-008XX

TC Art Unit: 1623

I hereby certify that this correspondence is being sent via
facsimile to Examiner Michael C. Henry, TC Art Unit 1623, Fax No.
(571) 273 8300, on Aug. 2, 2005.

08/10/2005 EFLORES 00000051 230804 10659063
01 FC:2252 225.00 DA

By: Holliday C. Heine
Holliday C. Heine, Ph.D.
Registration No. 34,346
Attorney for Applicant(s)

AMENDMENT UNDER 37 C.F.R. §1.116

Via Facsimile
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Final Office Action dated March 25, 2005,
please amend the above-identified patent application as follows.

08/10/2005 EFLORES 00000035 230804 10659063
01 FC:1252 450.00 DA

WEINGARTEN, SCHURGEN,
CARNEBLYN & LEBOVICI LLP
TEL. (617) 542-2290
FAX. (617) 451-0313